表紙
市場調査レポート

院内感染性肺炎(HAP) : パイプライン分析

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 271831
出版日 ページ情報 英文 131 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
院内感染性肺炎(HAP) : パイプライン分析 Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016
出版日: 2016年07月27日 ページ情報: 英文 131 Pages
概要

院内感染性肺炎(HAP)とは、入院中に感染した肺炎と定義されています。主な症状として、咳や発熱、体の震えを伴う悪寒、意識混濁、頭痛、食欲不振などが挙げられます。主なリスク要因には、慢性肺疾患や喫煙、認知症、脳卒中、脳外傷、心臓病、肝硬変、糖尿病などが含まれています。主な治療法として、抗生物質や生活習慣の改善などがあります。

当レポートでは、世界各国での院内感染性肺炎(HAP)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

院内感染性肺炎(HAP)の概要

治療薬の開発

  • 院内感染性肺炎向けパイプライン製品:概要
  • 院内感染性肺炎向けパイプライン製品:比較分析

各企業で開発中の院内感染性肺炎治療薬

各大学/研究機関で開発中の院内感染性肺炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

院内感染性肺炎治療薬:開発中の製品の一覧(企業別)

院内感染性肺炎治療薬:開発中の製品の一覧(大学/研究機関別)

院内感染性肺炎治療薬の開発に従事している企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • Dong-A Socio Group
  • MedImmune, LLC
  • Meiji Seika ファルマ
  • Melinta Therapeutics, Inc
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Tetraphase Pharmaceuticals Inc.

院内感染性肺炎:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (amikacin + fosfomycin)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • (ceftazidime + avibactam sodium)
  • (ceftolozane sulfate + tazobactam sodium)
  • AA-139
  • arbekacin
  • delafloxacin
  • eravacycline
  • iclaprim mesylate
  • lefamulin
  • MEDI-3902
  • MEDI-4893
  • molgramostim
  • Nu-2
  • Panaecin
  • plazomicin sulfate
  • pseudomonas + VAP vaccine
  • Pseudomonas aeruginosa vaccine
  • Qn-2251
  • relebactam
  • tedizolid phosphate
  • tosatoxumab
  • vancomycin hydrochloride

院内感染性肺炎治療薬:パイプライン製品の最新動向

院内感染性肺炎治療薬:開発が休止状態の製品

院内感染性肺炎治療薬:開発が中止された製品

院内感染性肺炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8303IDB

Summary

Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016', provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
  • The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects
  • The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hospital Acquired Pneumonia (HAP) Overview
  • Therapeutics Development
    • Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview
    • Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
  • Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies
  • Hospital Acquired Pneumonia (HAP) - Therapeutics under Investigation by Universities/Institutes
  • Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hospital Acquired Pneumonia (HAP) - Products under Development by Companies
  • Hospital Acquired Pneumonia (HAP) - Products under Investigation by Universities/Institutes
  • Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
    • Achaogen Inc.
    • Adenium Biotech ApS
    • Aridis Pharmaceuticals LLC
    • AstraZeneca Plc
    • Bayer AG
    • Cardeas Pharma Corp.
    • MedImmune, LLC
    • Meiji Seika Pharma Co., Ltd.
    • Melinta Therapeutics, Inc
    • Merck & Co., Inc.
    • Motif Bio Plc
    • Nabriva Therapeutics AG
    • Savara Inc.
    • Sealife PHARMA GMBH
    • Shionogi & Co., Ltd.
    • Tetraphase Pharmaceuticals Inc.
    • Wockhardt Limited
    • Zavante Therapeutics, Inc.
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amikacin sulfate + fosfomycin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (avibactam + ceftazidime) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (cilastatin sodium + imipenem + relebactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AA-139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aerucin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amikacin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbekacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefepime + zidebactam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosfomycin tromethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iclaprim mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lefamulin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-3902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-4893 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Panaecin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • panobacumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qn-2251 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-649266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosatoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vancomycin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WCK-2349 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WCK-771 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products
  • Hospital Acquired Pneumonia (HAP) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
      • Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
      • Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
      • Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
      • Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured
      • Oct 13, 2015: Motif Bio Announces Results of Two Posters on Iclaprim at ID Week 2015
      • Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015
      • Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
      • Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA
      • Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline's Potential Activity in Treating Serious Respiratory Infections
      • Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2016
  • Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp., H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co., Inc., H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc., H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Limited, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2016
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2016
  • Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top